CS
Candriam SCA Portfolio holdings
AUM
$17.3B
1-Year Return
21.68%
This Quarter Return
+5.62%
1 Year Return
+21.68%
3 Year Return
+102.54%
5 Year Return
+176.54%
10 Year Return
+489.52%
AUM
$16.5B
AUM Growth
+$861M
(+5.5%)
Cap. Flow
-$376M
Cap. Flow
% of AUM
-2.28%
Top 10 Holdings %
Top 10 Hldgs %
30.08%
Holding
747
New
44
Increased
335
Reduced
212
Closed
49
Top Buys
| 1 |
Eli Lilly
LLY
|
$68M |
| 2 |
Qualcomm
QCOM
|
$56.3M |
| 3 |
Nu Holdings
NU
|
$53.7M |
| 4 |
Amazon
AMZN
|
$49M |
| 5 |
Banco Macro
BMA
|
$43.2M |
Top Sells
| 1 |
Vipshop
VIPS
|
$599M |
| 2 |
Apple
AAPL
|
$46.1M |
| 3 |
Adobe
ADBE
|
$41.4M |
| 4 |
Starbucks
SBUX
|
$30M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$28.3M |
Sector Composition
| 1 | Technology | 33% |
| 2 | Healthcare | 27.47% |
| 3 | Financials | 9.69% |
| 4 | Consumer Discretionary | 7.72% |
| 5 | Industrials | 6.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
626
Vital Farms
VITL
$2.28B
| $287K | ﹤0.01% |
6,146
-6,993
| -53% | -$327K |
|
627
Pultegroup
PHM
$27.7B
| – | – |
0
| – | – |
|
628
Canadian Natural Resources
CNQ
$63.2B
| $281K | ﹤0.01% |
7,886
| – | – |
|
629
Genuine Parts
GPC
$19.4B
| $280K | ﹤0.01% |
2,023
+116
| +6% | +$16K |
|
630
International Paper
IP
$25.7B
| $277K | ﹤0.01% |
6,421
-713
| -10% | -$30.8K |
|
631
CytomX Therapeutics
CTMX
$376M
| $256K | ﹤0.01% |
+210,027
| New | +$256K |
|
632
KB Financial Group
KB
$28.5B
| $242K | ﹤0.01% |
4,279
-11,721
| -73% | -$663K |
|
633
HealthEquity
HQY
$7.88B
| $240K | ﹤0.01% |
+2,784
| New | +$240K |
|
634
American Eagle Outfitters
AEO
$3.26B
| $240K | ﹤0.01% |
+12,000
| New | +$240K |
|
635
BCE
BCE
$23.1B
| $234K | ﹤0.01% |
7,236
| – | – |
|
636
ASE Group
ASX
$22.8B
| $230K | ﹤0.01% |
+20,120
| New | +$230K |
|
637
Kinross Gold
KGC
$26.9B
| $228K | ﹤0.01% |
27,386
-11,179
| -29% | -$93K |
|
638
Texas Pacific Land
TPL
$20.4B
| $220K | ﹤0.01% |
300
-300
| -50% | -$220K |
|
639
Republic Services
RSG
$71.7B
| $201K | ﹤0.01% |
+1,032
| New | +$201K |
|
640
Gold Fields
GFI
$30.8B
| $189K | ﹤0.01% |
+12,675
| New | +$189K |
|
641
United Microelectronic
UMC
$17.1B
| $180K | ﹤0.01% |
+20,525
| New | +$180K |
|
|
GRAL
642
GRAIL, Inc. Common Stock
GRAL
$1.33B
| $160K | ﹤0.01% |
+10,431
| New | +$160K |
|
643
Banco Bradesco
BBD
$33.6B
| $115K | ﹤0.01% |
+51,535
| New | +$115K |
|
644
Nektar Therapeutics
NKTR
$764M
| $98.7K | ﹤0.01% |
+5,306
| New | +$98.7K |
|
645
CEMIG Preferred Shares
CIG
$5.84B
| $58.6K | ﹤0.01% |
+33,294
| New | +$58.6K |
|
646
Axsome Therapeutics
AXSM
$6.25B
| – | – |
-75,084
| Closed | -$5.99M |
|
647
BridgeBio Pharma
BBIO
$10.2B
| – | – |
-380,000
| Closed | -$11.7M |
|
648
Brown-Forman Class B
BF.B
$13.7B
| – | – |
0
| – | -$369K |
|
649
Acadia Pharmaceuticals
ACAD
$4.26B
| – | – |
-405,751
| Closed | -$7.5M |
|
650
Akero Therapeutics
AKRO
$3.58B
| – | – |
-240,000
| Closed | -$6.06M |
|